Blood centres cannot make cell therapies more accessible on their own. For decades they have partnered with hospitals to ...

Johnson & Johnson's recently approved combination of Rybrevant and Lazcluze has improved overall survival compared to ...

Where early enthusiasm around IDMP programmes had waned in response to slow progress from EMA in Europe towards clarifying ...

Chief executive David Zaccardelli said Ohtuvayre was off to an "exceptionally strong start," with more than 3,500 healthcare ...

Now, in 2025, we expect the life sciences industry will scale its use of GenAI with greater purpose. As these applications ...

The FDA has responded to the increasing use of artificial intelligence (AI) in the discovery and development of drugs and ...

1. Proactively identify barriers to medication adherence, including identifying and targeting patients who may be ...

The result is another major disappointment to ALS patients, who have limited drug treatment options at present, particularly ...

In a statement, Neumora revealed that the KOASTAL-1 study missed its primary endpoint, with navacaprant failing to achieve a ...

In a deal valued at up to $1 billion, Roche has licensed rights to a DLL3-directed antibody-drug conjugate (ADC) from China's ...

The JV was set up in 2001 and has become increasingly peripheral to Hutchmed's core business of developing novel therapies ...

Now, Novartis hopes to be able to share the data with regulatory authorities in 2025, including the US FDA, in the hope of ...